Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
split-virion pandemic influenza vaccine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 10 ug | EXPERIMENTAL | 10 microgram split-virion vaccine per dose |
| 15 ug | EXPERIMENTAL | 15 microgram split-virion vaccine per dose |
| 30 ug | EXPERIMENTAL | 30 microgram split-virion vaccine per dose |
| 5 ug | ACTIVE_COMPARATOR | 5 microgram whole-virion vaccine per dose |
| Name | Type | Description |
|---|---|---|
| split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | BIOLOGICAL | - |
Inclusion Criteria: * Healthy adolescent aged 12-17 years old * Be able to show legal identity card for the sake of recruitment * Volunteers or their parents are able to understand and sign the informed consent * Do not participate in other clinical trial Exclusion Criteria: * Any history of alle...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
The split-virion pandemic influenza vaccine is an investigational vaccine developed by Sinovac Biotech, Ltd for protection against pandemic influenza. It is based on the H5N1 strain NIBRG-14 and is designed for use in healthy volunteers, including children and adolescents. It is a vaccine candidate that has completed Phase 2 clinical testing in China.
The split-virion pandemic influenza vaccine is being developed for the prevention of influenza caused by pandemic H5N1 strains. Its clinical program has studied its use in healthy children and adolescents. It is intended to induce immune protection against pandemic influenza A (H5N1) virus.
The split-virion pandemic influenza vaccine is developed by Sinovac Biotech, Ltd, which trades under the ticker SVA. Sinovac is a China-based vaccine developer. The company conducted the Phase 2 clinical trials of this H5N1 pandemic influenza vaccine candidate in China.
The split-virion pandemic influenza vaccine is in Phase 2 development. Both of its clinical trials, NCT00900991 and NCT00900588, are completed, and no trials are currently active. It is an investigational vaccine and has not been approved by the FDA.
Two completed Phase 2 trials have evaluated the split-virion pandemic influenza vaccine: NCT00900991, which studied safety and immunogenicity in children aged 3 years and older, and NCT00900588, which studied safety and immunogenicity in adolescents aged 12 years and older. Both were randomized, double-blind, active-controlled trials conducted in China.
Yes. The split-virion pandemic influenza vaccine is also known as the split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14). The NIBRG-14 designation refers to the specific H5N1 vaccine strain used in this Sinovac Biotech candidate, so both names refer to the same investigational vaccine.